Matthew W. Tikonoff

Mergers & Acquisitions

  • Philips Healthcare in connection with numerous acquisitions and other strategic transactions
  • Netsmart Technologies, a health information technology provider, in its acquisitions of Lavender & Wyatt Systems and Trend Consulting Services
  • Belmont Instrument Corporation, a leading provider of fluid warming infusion systems, in its recapitalization transaction with Audax Private Equity
  • Jacqueline's Wholesale Bakery, Inc., a leading manufacturer of frozen cookie dough for the in-store bakery and foodservice channels, in connection with its sale to Rich Product Corporation
  • Molecular Templates, Inc. in its merger with Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
  • Associated Home Care, a private-duty home health aide provider, in its sale to Amedisys (NASDAQ: AMED)
  • Frazier Healthcare Ventures, a middle-market private equity firm, in its acquisition of a medical footware company
  • SiOnyx, a semiconductor process company, in its acquisition by a leading private equity firm
  • Edgile, a cybersecurity consulting firm, in a minority investment transaction with a leading private equity firm
  • A privately-held distributor of industrial supplies in its sale to a strategic competitor
  • Essilor International, an eyewear company, in its acquisition of Costa (NASDAQ: ATX)
  • FGX International, an eyewear company, in its acquisition of Stylemark
  • Dynasil Corporation of America (NASDAQ: DYSL) in the sale of its cancer medical probe business to Dilon Technologies and the sale of its x-ray fluorescence lead paint detector business to Protec
  • PTC (NASDAQ: PTC) in its acquisition of Enigma Information Systems
  • Ampersand Capital Partners in its acquisitions of numerous portfolio companies

Securities Offerings

  • Spero Therapeutics, Inc. (NASDAQ: SPRO) in its $75 million follow-on offering 5.2
  • Spero Therapeutics, Inc. (NASDAQ: SPRO) in its $83.6 million initial public offering 5.1
  • WAVE Life Sciences (NASDAQ: WVE) in its $102 million initial public offering
  • Lamar Advertising Company (NASDAQ: LAMR) in Rule 144A debt offerings and follow-on exchange offers
  • Stemline Therapeutics (NASDAQ: STML) in its $30 million initial public offering
Case Study

Mintz Advises Spero Therapeutics on Collaboration

Mintz advised biopharma company Spero Therapeutics on an agreement with Everest Medicines regarding the development and commercialization of a product to treat multidrug-resistant bacterial infections and option to license another.
Case Study

Mintz Guides Spero to Follow-On Offering

In July 2018 Mintz represented Spero Therapeutics, a multi-asset clinical stage biopharmaceutical company, in its underwritten public offering. The offering included 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock, with the gross proceeds to Spero being $75M prior to the deduction of any underwriting discounts and commissions.